Seven Potential Blockbuster Approvals To Look Out For In 2023

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.  

Piggy Money
The Seven Drugs Are All Novel Candidates That Could Reach Blockbuster Sales • Source: Shutterstock

Kicking off the list are three anti-amyloid antibody candidates vying to become an effective new treatment for for Alzheimer’s disease (AD) following the commercial failure of Biogen, Inc.’s Aduhelm (aducanumab). They are led by Eisai Co., Ltd. and Biogen’s lecanemab for which the firms have initiated a rolling biologics license application with the US Food and Drug Administration based on findings from a Phase IIb trial in 856 participants with early AD.

The trial showed lecanemab reduced brain amyloid by a mean of 0.306 SUVr units with more than 80% of subjects...

More from Innovation

More from In Vivo